Insulet Co. (NASDAQ:PODD) Shares Bought by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lifted its stake in shares of Insulet Co. (NASDAQ:PODD) by 13.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 71,765 shares of the medical instruments supplier’s stock after purchasing an additional 8,713 shares during the period. Segall Bryant & Hamill LLC’s holdings in Insulet were worth $18,736,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PODD. SBI Securities Co. Ltd. bought a new stake in shares of Insulet in the 4th quarter worth $36,000. SRS Capital Advisors Inc. raised its position in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 56 shares in the last quarter. TD Private Client Wealth LLC lifted its holdings in Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 56 shares during the last quarter. Friedenthal Financial bought a new position in shares of Insulet during the 4th quarter valued at about $57,000. Finally, Assetmark Inc. grew its stake in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock worth $69,000 after purchasing an additional 246 shares during the last quarter.

Insider Activity at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.47% of the stock is owned by company insiders.

Insulet Stock Performance

Shares of PODD stock opened at $272.71 on Wednesday. The firm has a market cap of $19.15 billion, a P/E ratio of 47.10, a PEG ratio of 3.62 and a beta of 1.29. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The stock’s 50-day moving average is $272.27 and its two-hundred day moving average is $258.19.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Analysts predict that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PODD has been the subject of several recent research reports. Piper Sandler increased their target price on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. StockNews.com cut Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Raymond James reaffirmed an “outperform” rating and set a $328.00 target price (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Wells Fargo & Company lifted their price target on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Finally, TD Cowen upped their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $292.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.